Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451644 | 0.82 | PRKCI (0.49) | PRKCIHTR7FFAR1CNR2NR1H2 | |
| SCHEMBL1508340 | 0.81 | HTR7 (0.59) | PRKCIHTR7FFAR1CNR2NR1H2 | |
| SCHEMBL205233 | 0.80 | CNR2 (0.48) | PRKCIHTR7FFAR1CNR2NR1H2 | |
| SCHEMBL688074 | 0.78 | PRKCI (0.53) | CYP11B1CYP11B2PRKCICHEK1 | |
| SCHEMBL16675765 | 0.77 | PRKCI (0.56) | CYP11B1CYP11B2PRKCIEGLN2IKBKB | |
| SCHEMBL28155307 | 0.76 | TSHR (0.46) | EGLN2 | |
| SCHEMBL12577779 | 0.75 | PRKCI (0.42) | PRKCIHTR7FFAR1CNR2NR1H2 | |
| SCHEMBL28011375 | 0.75 | FGFR1 (0.49) | PRKCIHTR7FFAR1CNR2NR1H2 | |
| SCHEMBL12577791 | 0.74 | HTR7 (0.51) | PRKCIHTR7FFAR1CNR2NR1H2 | |
| SCHEMBL13605867 | 0.74 | PRKCI (0.45) | CYP11B1CYP11B2PRKCICHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186909-A1 | Oxadiazolidinedione Compound | GPR119, GPR39, GPR65 | CYP11B1 327/4885CYP11B2 501/4885PRKCI 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.